Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study
Titel:
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study
Auteur:
Robert, Caroline Kicinski, Michal Dutriaux, Caroline Routier, Émilie Govaerts, Anne-Sophie Bührer, Emanuel Neidhardt, Eve-Marie Durando, Xavier Baroudjian, Barouyr Saiag, Philippe Gaudy-Marqueste, Caroline Ascierto, Paolo A Arance, Ana Russillo, Michelangelo Perrot, Jean-Luc Mortier, Laurent Aubin, Francois Dalle, Stéphane Grange, Florent Muñoz-Couselo, Eva Mary-Prey, Sorilla Amini-Adle, Mona Mansard, Sandrine Lebbe, Céleste Funck-Brentano, Elisa Monestier, Sandrine Eggermont, Alexander M M Oppong, Felix Wijnen, Leen Schilling, Bastian MandalÁ, Mario Lorigan, Paul van Akkooi, Alexander C J